Tyrosine kinase signalling in breast cancer - Tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer

被引:45
|
作者
Andrechek, ER
Muller, WJ
机构
[1] McMaster Univ, Dept Biol, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada
[2] McMaster Univ, Dept Pathol & Mol Med, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada
关键词
mammary gland; oncogene; signal transduction; transgenic mouse;
D O I
10.1186/bcr56
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The ability of growth factors and their cognate receptors to induce mammary epithelial proliferation and differentiation is dependent on their ability to activate a number of specific signal transduction pathways. Aberrant expression of specific receptor tyrosine kinases (RTKs) has been implicated in the genesis of a significant proportion of sporadic human breast cancers. Indeed, mammary epithelial expression of activated RTKs such as ErbB2/neu in transgenic mice has resulted in the efficient induction of metastatic mammary tumours. Although it is clear from these studies that activation these growth factor receptor signalling cascades are directly involved in mammary tumour progression, the precise interaction of each of these signalling pathways in mammary tumourigenesis and metastasis remains to be elucidated. The present review focuses on the role of several specific signalling pathways that have been implicated as important components in RTK-mediated signal transduction. In particular, it focuses on two well characterized transgenic breast cancer models that carry the polyomavirus middle T (PyV mT) and neu oncogenes.
引用
收藏
页码:211 / 216
页数:6
相关论文
共 50 条
  • [41] MODULATION OF TYROSINE KINASE SIGNALING PATHWAYS IN HUMAN BREAST-CANCER CELLS
    DALY, RJ
    BINDER, MD
    JANES, PW
    SUTHERLAND, RL
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 237 - 237
  • [42] The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells
    Peter J. P. Coopman
    Michael T. H. Do
    Mara Barth
    Emma T. Bowden
    Andrew J. Hayes
    Eugenia Basyuk
    Jan K. Blancato
    Phyllis R. Vezza
    Sandra W. McLeskey
    Paul H. Mangeat
    Susette C. Mueller
    Nature, 2000, 406 : 742 - 747
  • [43] Fas-signaling and effects on receptor tyrosine kinase signal transduction in human breast epithelial cells
    Shen, K
    Novak, RF
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 230 (01) : 89 - 93
  • [44] Activator signal research in Syk tyrosine kinase, a suppresor candidate of tumors in breast cancer
    Gallud, A.
    Bettache, N.
    Morel, A.
    Urbach, S.
    Montcourrier, P.
    Coopman, P.
    BULLETIN DU CANCER, 2011, 98 : S22 - S22
  • [45] Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer
    Mukherjee, A.
    Dhadda, A. S.
    Shehata, M.
    Chan, Stephen
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (13) : 2189 - 2204
  • [46] Autophagic regulation of the Met receptor tyrosine kinase in breast cancer
    Bell, Emily S.
    Zuo, Dongmei
    Park, Morag
    CANCER RESEARCH, 2014, 74 (19)
  • [47] Significance of Tyrosine Kinase Inhibitors in the Treatment of Metastatic Breast Cancer
    Mundhenke, Christoph
    Strauss, Alexander
    Schem, Christian
    BREAST CARE, 2009, 4 (06) : 373 - 378
  • [48] HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer
    Arteaga, CL
    Moulder, SL
    Yakes, FM
    SEMINARS IN ONCOLOGY, 2002, 29 (03) : 4 - 10
  • [49] Lapatinib: A dual tyrosine kinase inhibitor for metastatic breast cancer
    Paul, Betsy
    Trovato, James A.
    Thompson, Jennifer
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2008, 65 (18) : 1703 - 1710
  • [50] A review on tyrosine kinase inhibitors for targeted breast cancer therapy
    Sankarapandian, Vidya
    Rajendran, Ramya Lakshmi
    Miruka, Conrad Ondieki
    Sivamani, Poornima
    Maran, Balu Alagar Venmathi
    Krishnamoorthy, Rajapandiyan
    Gangadaran, Prakash
    Ahn, Byeong-Cheol
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 263